Compare Abbott Laboratories (ABT) vs FirstEnergy Corp. (FE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs FirstEnergy Corp. — how do they compare? Abbott Laboratories trades at $95.3 (market cap $166.94B), while FirstEnergy Corp. trades at $48.11 (market cap $27.99B). The key difference: Abbott Laboratories is far larger — about 6× FirstEnergy Corp.'s market cap, and FirstEnergy Corp. pays the higher dividend (3.84%). Which is the better fit depends on your goals.
| ABT | FE | |
|---|---|---|
Market Cap | $166.94B | $27.99B |
Sector | Health | Utilities |
52-Week High | $136.62 | $51.91 |
52-Week Low | $82.57 | $39.89 |
Enterprise Value | $193.69B | $56.00B |
Dividend Yield | 2.63% | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
FirstEnergy (FE) trades at $48.39, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $52.25. The company reported revenue of $15.09 billion in 2025, with net income of $1.02 billion, and recent earnings have mostly beaten expectations. Positive news highlights growth from data center demand and a $36 billion investment plan for grid upgrades.
The outlook is supported by earnings visibility and strategic investments, but risks include regulatory uncertainty and high debt levels. With no sell ratings from analysts and a dividend payout scheduled, FE presents a steady utility investment with moderate upside potential balanced by sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
